Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rifkin

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|September 30, 2021
Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM RegistryCristina Gasparetto, Sundar Jagannath, Robert M Rifkin, et al.
Cancer|July 25, 2020
Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysisSikander Ailawadhi, Sundar Jagannath, Hans C Lee, et al.
Practical Radiation Oncology|November 20, 2023
Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM RegistryLeslie Ballas, Sikander Ailawadhi, Mohit Narang, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 27, 2024
Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the Connect<sup>Ⓡ</sup> MM RegistryHoward R Terebelo, James Omel, Lynne I Wagner, et al.
Future Oncology (London, England)|March 1, 2019
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myelomaCaitlin Costello, Faith E Davies, Gordon Cook, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 11, 2020
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to IxazomibSudhir Manda, Habte A Yimer, Stephen J Noga, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 25, 2022
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease RegistryHans C Lee, Karthik Ramasamy, Katja Weisel, et al.
Ejhaem|November 29, 2023
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trialPaul G Richardson, Thierry Facon, Christopher P Venner, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 11, 2025
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal AntibodyKarthik Ramasamy, Ravi Vij, David Kuter, et al.
Blood|March 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Christopher P Venner, Nizar J Bahlis, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Clinical Lymphoma, Myeloma & Leukemia|September 30, 2021
Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM RegistryCristina Gasparetto, Sundar Jagannath, Robert M Rifkin, et al.
Cancer|July 25, 2020
Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysisSikander Ailawadhi, Sundar Jagannath, Hans C Lee, et al.
Practical Radiation Oncology|November 20, 2023
Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM RegistryLeslie Ballas, Sikander Ailawadhi, Mohit Narang, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 27, 2024
Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the Connect<sup>Ⓡ</sup> MM RegistryHoward R Terebelo, James Omel, Lynne I Wagner, et al.
Future Oncology (London, England)|March 1, 2019
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myelomaCaitlin Costello, Faith E Davies, Gordon Cook, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 11, 2020
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to IxazomibSudhir Manda, Habte A Yimer, Stephen J Noga, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 25, 2022
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease RegistryHans C Lee, Karthik Ramasamy, Katja Weisel, et al.
Ejhaem|November 29, 2023
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trialPaul G Richardson, Thierry Facon, Christopher P Venner, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 11, 2025
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal AntibodyKarthik Ramasamy, Ravi Vij, David Kuter, et al.
Blood|March 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Christopher P Venner, Nizar J Bahlis, et al.
Pageof 9